Interv Akut Kardiol. 2018;17(4):243-244

The RELAX-AHF-2 Trial: RELAXin in Acute Heart Failure-2

Lenka Špinarová¹, Jiří Špinar²

¹ I. interní kardioangiologická klinika, FN u svaté Anny a lékařská fakulta Masarykovy Univerzity, Brno

² Interní kardiologická klinika FN Brno a lékařská fakulta Masarykovy Univerzity, Brno

Serelaxin is a recombinant form of human relaxin-2 with favourable haemodynamic properties. The RELAX-AHF trial raised hopethat this agent could affect the mortality rates in patients with acute decompensated heart failure. The RELAX-AHF-2 trial wasintended to confirm this assumption. The trial studied the administration of serelaxin against placebo in patients with acute heartfailure. After adding this agent to the standard medication for heart failure, there was no clinical improvement by day 5 of hospitalizationas well as no reduction in the 180-day cardiovascular mortality rate in the patients. Likewise, there was no reduction inthe overall 180-day mortality rate or no shortening of the hospital stay. The drug was well tolerated, with adverse effects beingcomparable to those of placebo.

Keywords: acute heart failure, serelaxin, cardiovascular mortality, overall mortality, administration safety

Received: September 9, 2018; Accepted: October 3, 2018; Published: December 1, 2018  Show citation